Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial (Q44074467)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

phase III clinical trial

0 references

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Li Zhang

1

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Shenglin Ma

2

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Xiangqun Song

3

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Baohui Han

4

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Ying Cheng

5

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Cheng Huang

6

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Shujun Yang

7

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Xiaoqing Liu

8

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Yunpeng Liu

9

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Shun Lu

10

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Jie Wang

11

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Shucai Zhang

12

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Caicun Zhou

13

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Xiangwei Zhang

14

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Nobuya Hayashi

15

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Mengzhao Wang

16

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

INFORM investigators

17

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

publication date

17 April 2012

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

466-475

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970117-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970117-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970117-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970117-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970117-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970117-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970117-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970117-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970117-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970117-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group tr

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970117-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970117-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970117-1

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970117-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970117-1

7 January 2021

based on heuristic

inferred from DOI database lookup

What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970117-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970117-1

7 January 2021

based on heuristic

inferred from DOI database lookup

A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970117-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970117-1

7 January 2021

based on heuristic

inferred from DOI database lookup

International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970117-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970117-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, r

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970117-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970117-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970117-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970117-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction pemetrexed and cisplatin followed by maintenance pemetrexed versus carboplatin plus paclitaxel plus bevacizumab followed by maintenance bevacizumab: a quality of life-oriented randomized phase III study in patients with advanced non-squamo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970117-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(12)70117-1

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44074467&oldid=2106299231"